SEC Filing Summary: Maravai LifeSciences Holdings, Inc. (MRVI)
Business Context and Reporting Period
This Form 8-K, dated March 17, 2025, reports on Maravai LifeSciences Holdings, Inc., a Delaware corporation. The filing primarily addresses the announcement of financial results for the fourth quarter and full fiscal year ended December 31, 2024, and a material restatement of prior interim financial statements.
Key Financial Metrics and Restatement Details
The filing does not provide specific revenue, profit, cash flow, or debt figures for the current period, as these are contained in the press release (Exhibit 99.1) and the concurrent Form 10-K. However, it discloses a specific financial correction:
- Restatement Amount: Approximately $3.9 million in revenue.
- Correction Nature: Revenue was incorrectly recorded in the final week of Q2 2024 upon shipment instead of the first week of Q3 2024 upon customer receipt.
- Impact: This error affects the interim financial statements for the quarters ended June 30, 2024, and September 30, 2024.
Material Changes and Internal Controls
The Audit Committee concluded that the interim financial statements for Q2 and Q3 2024 should no longer be relied upon. Consequently, the Company has identified material weaknesses in its internal control over financial reporting. As of December 31, 2024, the Company determined that its disclosure controls and procedures were not effective at a reasonable assurance level.
Outlook, Risks, and Management Commentary
Management has discussed the restatement and internal control deficiencies with the independent registered public accounting firm, Ernst & Young LLP. The filing notes that the restatement details are set forth in Note 18 of the consolidated financial statements in the 2024 Form 10-K. No specific forward-looking guidance or outlook is provided within the text of this 8-K.
Investor Verification Checklist
- Verify the specific Q4 and full-year 2024 financial results in the press release (Exhibit 99.1) and the concurrent Form 10-K.
- Review Note 18 of the 2024 Form 10-K for the detailed impact of the $3.9 million revenue restatement on Q2 and Q3 2024 earnings.
- Examine Part II, Item 9A of the 2024 Form 10-K for a full description of the material weaknesses in internal controls and the remediation plan.
- Confirm the status of the concurrent filing of the 2024 Form 10-K to ensure the restated financials are available.